Matthew Lunning, DO, FACP

Interim Chief, UNMC Division of Hematology
Professor, UNMC Division of Hematology
UNMC Assistant Vice Chancellor of Clinical Research

Dr. Matt Lunning serves as Interim Chief and Professor in the UNMC Division of Hematology. A leader in hematologic malignancies, Dr. Lunning’s clinical and research focus encompasses non-Hodgkin lymphoma, Hodgkin disease, cellular immunotherapies including CAR-T therapy and benign hematologic disorders.

In addition to his divisional leadership, Dr. Lunning is the Assistant Vice Chancellor of Clinical Research at UNMC, where he oversees initiatives that strengthen the institution’s translational and clinical research enterprise. He also contributes to institutional governance as an elected at-large member of the Nebraska Medicine Medical Executive Committee.

Dr. Lunning earned his Doctor of Osteopathic Medicine degree from Des Moines University in 2006. He completed his internal medicine residency at UNMC, serving as Chief Medical Resident, followed by a Hematology/Oncology fellowship at Memorial Sloan Kettering Cancer Center where he was selected as Hematology Chief Fellow.

Since returning to UNMC in 2013, Dr. Lunning has distinguished himself as a clinician, educator and investigator. His research program focuses on advancing novel therapeutic strategies for lymphoma and multiple myeloma, as well as expanding access to cellular therapies in the Midwest. His commitment to scientific advancement and mentorship was recognized with the UNMC Distinguished Scientist Award in 2019.

Nationally, Dr. Lunning contributes his expertise through service on multiple National Comprehensive Cancer Network guideline committees, including the Immunotherapy Toxicity and T-cell Lymphoma panels, helping shape evidence-based standards of care for patients worldwide. He has also served as an invited member of the American Society of Clinical Oncology Cancer Education Committee for Non-Hodgkin Lymphoma, where he played a key role in developing educational programming for oncology professionals.

Beyond his institutional and national roles, Dr. Lunning is the co-organizer of the Pan Pacific Lymphoma Conference, one of the largest international meetings dedicated to the latest advances in lymphoma research and treatment. Through his leadership, innovation and dedication to patient-centered care, Dr. Lunning continues to elevate hematology and oncology practice regionally and globally.